Literature DB >> 29628265

Dysfunction of antigen processing and presentation by dendritic cells in cancer.

Joanna Bandola-Simon1, Paul A Roche2.   

Abstract

The ability to mount an effective anti-tumor immune response requires coordinate control of CD4 T cell and CD8 T cell function by antigen presenting cells (APCs). Unfortunately, tumors create an immunosuppressive microenvironment that helps protect tumor cells from immune recognition. In many cases this defect can be traced back to a failure of APCs (most importantly dendritic cells (DCs)) to recognize, process, and present tumor antigens to T cells. In this review, we will summarize work addressing the role of different DC subsets in anti-tumor immunity and the various mechanisms used by tumor cells to suppress the ability of APCs to stimulate potent anti-tumor T cell responses.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antigen processing and presentation; Cancer

Mesh:

Substances:

Year:  2018        PMID: 29628265      PMCID: PMC6173666          DOI: 10.1016/j.molimm.2018.03.025

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  116 in total

Review 1.  Immunological aspects of cancer chemotherapy.

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

2.  Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategies.

Authors:  Francois Ghiringhelli; Lionel Apetoh
Journal:  Future Oncol       Date:  2013-04       Impact factor: 3.404

3.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Authors:  Stefani Spranger; Daisy Dai; Brendan Horton; Thomas F Gajewski
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

Review 4.  The IL-17 pathway as a major therapeutic target in autoimmune diseases.

Authors:  Yan Hu; Fang Shen; Natasha K Crellin; Wenjun Ouyang
Journal:  Ann N Y Acad Sci       Date:  2010-12-13       Impact factor: 5.691

5.  Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL.

Authors:  Caroline Aspord; Marie-Therese Leccia; Julie Charles; Joel Plumas
Journal:  Cancer Immunol Res       Date:  2013-09-26       Impact factor: 11.151

Review 6.  Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?

Authors:  Marie de Charette; Aurélien Marabelle; Roch Houot
Journal:  Eur J Cancer       Date:  2016-10-15       Impact factor: 9.162

7.  Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells.

Authors:  Ana S López; Estibaliz Alegre; Joël LeMaoult; Edgardo Carosella; Alvaro González
Journal:  Mol Immunol       Date:  2006-02-21       Impact factor: 4.407

8.  Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania.

Authors:  Beatriz León; María López-Bravo; Carlos Ardavín
Journal:  Immunity       Date:  2007-04-05       Impact factor: 31.745

9.  Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.

Authors:  David Escors
Journal:  New J Sci       Date:  2014-01-05

10.  Monocyte-Derived Dendritic Cells Are Essential for CD8(+) T Cell Activation and Antitumor Responses After Local Immunotherapy.

Authors:  Sabine Kuhn; Jianping Yang; Franca Ronchese
Journal:  Front Immunol       Date:  2015-11-23       Impact factor: 7.561

View more
  22 in total

1.  Induction of Immune Response Against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibody (MBTA).

Authors:  Rogelio Medina; Herui Wang; Veronika Caisová; Jing Cui; Iris H Indig; Ondrej Uher; Juan Ye; Anthony Nwankwo; Victoria Sanchez; Tianxia Wu; Edjah Nduom; John Heiss; Mark R Gilbert; Masaki Terabe; Winson Ho; Jan Zenka; Karel Pacak; Zhengping Zhuang
Journal:  Adv Ther (Weinh)       Date:  2020-06-09

2.  Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes.

Authors:  Chunmei Fu; Peng Peng; Jakob Loschko; Li Feng; Phuong Pham; Weiguo Cui; Kelvin P Lee; Anne B Krug; Aimin Jiang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-02       Impact factor: 11.205

3.  Lipid Metabolism and Tumor Antigen Presentation.

Authors:  Hong Qin; Yaxi Chen
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Virus-Based Immuno-Oncology Models.

Authors:  Juliana Sitta; Pier Paolo Claudio; Candace M Howard
Journal:  Biomedicines       Date:  2022-06-18

Review 5.  Immune checkpoint inhibitors for the treatment of melanoma.

Authors:  Francesco Sabbatino; Luigi Liguori; Stefano Pepe; Soldano Ferrone
Journal:  Expert Opin Biol Ther       Date:  2022-02-13       Impact factor: 5.589

6.  Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity.

Authors:  Farideh Ordikhani; Mayuko Uehara; Vivek Kasinath; Li Dai; Siawosh K Eskandari; Baharak Bahmani; Merve Yonar; Jamil R Azzi; Yousef Haik; Peter T Sage; George F Murphy; Nasim Annabi; Tobias Schatton; Indira Guleria; Reza Abdi
Journal:  JCI Insight       Date:  2018-10-18

Review 7.  Messing with the Sentinels-The Interaction of Staphylococcus aureus with Dendritic Cells.

Authors:  Murthy N Darisipudi; Maria Nordengrün; Barbara M Bröker; Vincent Péton
Journal:  Microorganisms       Date:  2018-08-15

Review 8.  Fates of CD8+ T cells in Tumor Microenvironment.

Authors:  Nomathamsanqa Resegofetse Maimela; Shasha Liu; Yi Zhang
Journal:  Comput Struct Biotechnol J       Date:  2018-11-22       Impact factor: 7.271

Review 9.  Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.

Authors:  Chunmei Fu; Aimin Jiang
Journal:  Front Immunol       Date:  2018-12-20       Impact factor: 7.561

Review 10.  Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential.

Authors:  Espen Basmo Ellingsen; Sara M Mangsbo; Eivind Hovig; Gustav Gaudernack
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.